newsfilter
← Latest News
Business Wire·

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

–Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – – Authorization Based on